Pediatric Gaucher disease type I and mild growth hormone deficiency: a new feature?
A 5-year-old girl was referred to the Department of Pediatrics and Neonatology, Guglielmo da Saliceto Hospital, Italy, because of growth retardation. Clinical and laboratory investigations showed pallor, hepatosplenomegaly, anemia and low/normal platelet count. Further investigations led to the diagnosis of Gaucher disease (GD). We believe this is the first report of growth hormone deficiency in a growth-retarded child with GD. After 1 year of imiglucerase replacement enzyme therapy, her bone age had normalized, linear growth rate had accelerated, and insulin growth factor-1 (IGF-1) and, perhaps more interestingly, growth hormone deficiency, had normalized. While the pathophysiological mechanisms underlying compromised growth in GD are poorly understood, the response to imiglucerase reported in this patient suggests that growth hormone deficiency is related to the underlying metabolic disorder in GD, rather than a primary endocrine pathology. Growth hormone deficiency adds to an already extensive list of possible clinical manifestations of this heterogeneous and complex disorder.
Biasucci
Giacomo
G
Department of Pediatrics and Neonatology, Guglielmo da Saliceto Hospital, Cantone del Cristo 50, 29100 Piacenza, Italy. g.biasucci@ausl.pc.it
Manfredi
Piera
P
D001827:Body Height / Q000187:drug effects; D002675:Child, Preschool; D056947:Enzyme Replacement Therapy; D005260:Female; D005776:Gaucher Disease / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D005962:Glucosylceramidase / Q000627:therapeutic use; D006130:Growth Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D019382:Human Growth Hormone / Q000097:blood / Q000172:deficiency*; D006801:Humans; D013997:Time Factors; D016896:Treatment Outcome
D019382:Human Growth Hormone; D005962:Glucosylceramidase; C090568:imiglucerase